Home / Stocks / MET

MetLife (MET, Life & Health Insurance) Stock Valuation & Fair Value Fairly valued

MetLife (MET, Life & Health Insurance) trades at a blended P/E of 10.0, about 6% above its historical normal valuation, with a forward growth estimate of 11.2% and a PEG of 0.90. Analysts' one-year estimates have been hit 27% of the time.

No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.

DATA AS OF 2026-08-28

Blended P/E

10.0

Normal P/E

9.5

PEG

0.90

Fwd growth

11.2%

Div yield

2.5%

RSI (14)

55.9

Neutral

The Street vs SeerForecast

Wall Street's mean price target for MET is $104.38 across 16 analysts, 8.1% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

No notable valuation flags.

Verdict history

tickerseer's rating has been fairly valued since 2026-06-03.

Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 8.9-7%Fairly valued

2026-06-10P/E 9.1-4%Fairly valued

2026-06-14P/E 9.1-4%Fairly valued

2026-06-16P/E 9.1-4%Fairly valued

2026-06-21P/E 9.1-4%Fairly valued

2026-07-02P/E 9.3-2%Fairly valued

2026-07-06P/E 9.6+1%Fairly valued

2026-07-09P/E 9.6+1%Fairly valued

2026-07-12P/E 9.8+3%Fairly valued

2026-07-13P/E 9.8+3%Fairly valued

2026-07-14P/E 9.8+3%Fairly valued

2026-07-20P/E 10.0+5%Fairly valued

2026-07-22P/E 10.0+5%Fairly valued

2026-07-25P/E 10.1+6%Fairly valued

2026-07-27P/E 10.1+6%Fairly valued

2026-07-31P/E 10.3+9%Fairly valued

2026-08-03P/E 10.2+8%Fairly valued

2026-08-07P/E 10.6+11%Fairly valued

2026-08-10P/E 10.3+9%Fairly valued

2026-08-14P/E 10.2+7%Fairly valued

2026-08-17P/E 10.2+8%Fairly valued

2026-08-21P/E 9.8+3%Fairly valued

2026-08-24P/E 9.9+4%Fairly valued

2026-08-27P/E 9.9+4%Fairly valued

2026-08-28P/E 10.0+6%Fairly valued ← now

Frequently asked questions

Is MetLife stock overvalued?

At a blended P/E of 10.0 versus its historical normal P/E of 9.5, MetLife trades about 6% above its typical valuation, with a PEG of 0.90 on 11.2% forward growth. tickerseer currently rates it fairly valued.

What is MetLife's fair value and PEG?

MetLife trades at a blended P/E of 10.0 against a historical normal P/E of 9.5, a PEG of 0.90, and a forward growth estimate of 11.2%.

Has tickerseer's rating of MetLife changed?

tickerseer's rating has been fairly valued since 2026-06-03.

What is the analyst price target for MetLife?

The mean Wall Street price target for MetLife is $104.38 across 16 analysts, 8.1% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Life & Health Insurance. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track MET free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.